tbuckley/cabot-search huggingface dataset:
P2-11-03: High Expression of CX3CL1 by Tumor Cells Correlates with a Good Prognosis and Increased Infiltrating CD8+ T Cells, Natural Killer Cells, and Dendritic Cells in Breast Carcinoma.
Authors: JS Lee, MH Park, JH Yoon
Journal: Cancer Research (2011)

Abstract CX3CL1 is the only CX3C chemokine that can chemoattract CD8+ T cells, natural killer (NK) cells, and dendritic cells (DCs). Although studies have reported that CX3CL1 regulates the host immune response, the roles of the CX3CL1 in breast carcinoma remain unknown. We evaluated the expression CX3CL1 in 198 surgical specimens of breast carcinoma and analyzed any association with the clinicopathological factors, including CD8+ T cells, CD56+ NK cells, and CD1a+ DCs, while also evaluating the impact on the prognosis. High CX3CL1 expression was found in 136 of 198 (68.7%) breast carcinomas. The numbers of stromal CD8+ T cells, intratumoral CD1a+ DCs, and stromal CD56+ NK cells were significantly increased in the high CX3CL1 expression group (19.3 ± 15.2, 0.3 ± 0.9 and 1.4 ± 1.7 per field, respectively) compared with the low expression group (10.2 ± 13.1, 0.0 ± 0.3 and 0.7 ± 0.8 per field, respectively). Patients with high CX3CL1 expression had a significantly better prognosis for disease-free and overall survival than those with low expression (P = 0.002 and P = 0.000, respectively). In a multivariate analysis, the CX3CL1 expression was identified as one of the independent prognostic factors for overall survival (odds ratio, 2.29; P = 0.002). These data suggest that CX3CL1 expressed in the tumor cells appears to enhance the recruitment of CD8+ T cells, NK cells, and CD1a+ DCs, thereby bringing about a better prognosis in breast carcinoma. CX3CL1 is a new prognostic biomarker and be a novel candidate for development of a more effective therapeutic strategy for breast carcinoma. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-11-03.
ARRHYTHMIA BURDEN AMONG COMMUNITY DWELLING ELDERLY USING TWO WEEKS OF AMBULATORY ECG RECORDINGS
Authors: Sunil K. Agarwal, Lin Chen, Alvaro Alonso, Faye Lopez, Elsayed Soliman, Chiadi Ndumele, Laura Loehr, Larisa Tereshchenko, Hugh Calkins, Gerardo Heiss, Josef Coresh
Journal: Journal of the American College of Cardiology (2015)
SAT0283 The Incidence of GIANT Cell Arteritis in Slovenia
Authors: N. Potočnik, Ž. Rotar, A. Hočevar, J. Pižem, M. Hawlina, A. Fakin, M. Tomšič
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Giant cell arteritis (GCA) is the most common systemic vasculitis in adults aged 50 years or above. Annual incidence rates vary widely from 6.9–76.6 per 10<sup>5</sup> of adults in this age group, depending on the region.<sup>1</sup> <h3>Objectives</h3> To determine the incidence rate of GCA in our population. <h3>Methods</h3> We prospectively collected incident cases of GCA from January 1st 2011 to December 31st 2012 at our department of rheumatology which is a part of an integrated secondary/tertiary university teaching hospital that is the only referral center serving a region representing approximately a quarter of the national adult population. Additionally, newly diagnosed cases of GCA between January 1st 2009 and December 31st 2010 were retrospectively identified by searching the electronic patient records for ICD-10 codes M31.5 and M31.6 at our department. The retrospective approach and search strategy was also applied on electronic medical records at the departments of infectious diseases and ophthalmology between January 1st 2009 and December 31st 2012. To further reduce possibility of underreporting, the attached medical faculty9s Institute of Pathology provided a list of all temporal artery biopsies examined during the observation period which were then cross-referenced with the hospital9s electronic medical records. Annual incidence rate for GCA was then calculated. <h3>Results</h3> During the four year observation period we identified 97 new cases of GCA (68% female; mean (SD) age 75.6 (8.1) years) from a well-defined adult white Caucasian population of 232,041 inhabitants aged 50 or above. The temporal artery biopsy was consistent with GCA, negative or not performed in 75.3%, 18.6, and 6.2% of cases, respectively. Thus, the annual incidence of GCA in our population is 10.5 (95% CI 8.5–12.7), and 4.7 (95% CI 3.8–5.7) per 10<sup>5</sup> adults aged 50, and 20 years or above, respectively. <h3>Conclusions</h3> The annual incidence rate of 10.5 per 10<sup>5</sup> adults aged 50 or above makes GCA the most common systemic vasculitis in this age group of our population. Although the GCA almost exclusively affects adults over 50 years of age, the incidence rate of 4.7 per 10<sup>5</sup> adults aged 20 and above, also makes it the most common systemic vasculitis in the adult population overall, with IgA vasculitis coming a close second with 3.7 per 10<sup>5</sup> adults aged 20 years or above. <h3>References</h3> Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ et al. Epidemiology of Giant Cell Arteritis and Polymyalgia Rheumatica. Arthritis Rheum 2009;61:1454-61. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1968
1197 MK-5172 IN COMBINATION WITH PEG-INTERFERON/RIBAVIRIN DEMONSTRATES ROBUST EFFICACY AND A LOW RATE OF RESISTANCE-ASSOCIATED VIROLOGIC FAILURE IN TREATMENT NAÏVE GENOTYPE 1 CHRONIC HCV-INFECTED PATIENTS
Authors: A. Howe, S. Ludmerer, R. Liu, S. Black, R. Barnard, W. Newhard, D. Graham, D. Nickle, P. Hwang, C. Gilbert, N. Mobashery
Journal: Journal of Hepatology (2013)
P34 What Is Integrated Care And What Is The Value Of An Integrated Respiratory Specialist?
Authors: N. Roberts, M. Ward, I. Patel, J. Yorke, J. Williams, R. Walters, M. McKevitt, S. Edwards
Journal: Thorax (2014)

<h3>Aim</h3> The way we deliver healthcare in the UK is changing, joining up care between the different health sectors has created a new field of “integrated care”. Recent publications from the Kings Fund, Nuffield Trust and National Voices has shown that it is difficult to define “integrated care”. This project surveyed health professionals on their views about integrated care and the value of integrated respiratory specialists. <h3>Method</h3> A questionnaire was sent to all BTS members in Oct 2013 on the role of integrated care specialists, 216 responses were received. <h3>Results</h3> Most respondents (82.5%, 178/216) included integration of primary and secondary care in their definition of integrated care, only 36.5% (65/178) included community, and a smaller number included social care as part of the definition. In the free-text there was also emphasis on the bridging role of the post, and providing “seamless care” across sectors. 62% (86/139) agreed that integrated respiratory specialists had added value (compared to respiratory specialist roles); providing continuity of care for a defined population (87%, [121/139), and 77% (106/138) agreed that they improve outcomes for patients with a long term condition. Eighty-nine percent (124/140) also agreed that integrated specialists improve relationships between primary and secondary care. When asked the most important role that an integrated respiratory specialist should undertake (98 comments), the provision of specialist leadership, clinical decision-making and supervision (20 comments) were highly rated. Teaching (10 comments) and providing liaison support for the whole pathway were also important (9 comments). <h3>Conclusion</h3> 82% of respondents (178/216) included integration of primary and secondary care in their definition of integrated care. However 14.4% were unsure of what integrated care was. Considerable more work is needed to promote this new way of working and potential career pathway. However of those who did know about these roles, a large majority agreed that these roles had added value compared to traditional specialist roles. Funded by the BTS. <h3>Abstracts M35 to M43 can be found on pages A208–A211.</h3>
Phase III Trials of Photodynamic Therapy Now Under Way
Authors: Philippe Chemaly
Journal: JNCI Journal of the National Cancer Institute (1989)

Phase III Trials of Photodynamic Therapy Now Under Way Philippe Chemaly Philippe Chemaly Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 13, 5 July 1989, Pages 975–977, https://doi.org/10.1093/jnci/81.13.975 Published: 05 July 1989
Cognition in Hilbert space
Authors: Bruce James MacLennan
Journal: Behavioral and Brain Sciences (2013)

Abstract Use of quantum probability as a top-down model of cognition will be enhanced by consideration of the underlying complex-valued wave function, which allows a better account of interference effects and of the structure of learned and ad hoc question operators. Furthermore, the treatment of incompatible questions can be made more quantitative by analyzing them as non-commutative operators.
SP0170 Where do these new treatments fit in the treatment paradigm - how do they match up to biologic DMARDS?
Authors: I.B. McInnes
Journal: Annals of the Rheumatic Diseases (2013)

The advent of new orally bioavailable kinase inhibitors will impact shortly on the strategies that we employ in the treatment of rheumatoid arthritis. The position that they occupy in the treatment paradigms will be influenced by their efficacy, safety profile, cost and their ability to combine with other medications related to arthritis treatment and to other co-morbid conditions. This lecture will review their potential value in each of these domains. <h3>Disclosure of Interest</h3> None Declared
Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds
Authors: Elena Nikiphorou, Sam Norton, Adam Young, Lewis Carpenter, Josh Dixey, David Andrew Walsh, Patrick Kiely
Journal: Annals of the Rheumatic Diseases (2016)

To examine the association between disease activity in early rheumatoid arthritis (RA), functional limitation and long-term orthopaedic episodes.Health Assessment Questionnaire (HAQ) disability scores were collected from two longitudinal early RA inception cohorts in routine care; Early Rheumatoid Arthritis Study and Early Rheumatoid Arthritis Network from 1986 to 2012. The incidence of major and intermediate orthopaedic surgical episodes over 25 years was collected from national data sets. Disease activity was categorised by mean disease activity score (DAS28) annually between years 1 and 5; remission (RDAS≤2.6), low (LDAS>2.6-3.2), low-moderate (LMDAS≥3.2-4.19), high-moderate (HMDAS 4.2-5.1) and high (HDAS>5.1).Data from 2045 patients were analysed. Patients in RDAS showed no HAQ progression over 5 years, whereas there was a significant relationship between rising DAS28 category and HAQ at 1 year, and the rate of HAQ progression between years 1 and 5. During 27 986 person-years follow-up, 392 intermediate and 591 major surgeries were observed. Compared with the RDAS category, there was a significantly increased cumulative incidence of intermediate surgery in HDAS (OR 2.59 CI 1.49 to 4.52) and HMDAS (OR 1.8 CI 1.05 to 3.11) categories, and for major surgery in HDAS (OR 2.48 CI 1.5 to 4.11), HMDAS (OR 2.16 CI 1.32 to 3.52) and LMDAS (OR 2.07 CI 1.28 to 3.33) categories. There was no significant difference in HAQ progression or orthopaedic episodes between RDAS and LDAS categories.There is an association between disease activity and both poor function and long-term orthopaedic episodes. This illustrates the far from benign consequences of persistent moderate disease activity, and supports European League Against Rheumatism treat to target recommendations to secure low disease activity or remission in all patients.
Pulmonary 18F-FDG Microembolism Detected on Only Delayed Image in a PET/CT Study
Authors: Gozde Daglioz Gorur, Esra Ciftci, Serkan Isgoren, Hakan Demir, Cagla Haksal
Journal: Clinical Nuclear Medicine (2014)

Focal 18F-FDG pulmonary uptake on PET without corresponding abnormality on CT is an incidental and rare finding. This artifact is associated with iatrogenic FDG microembolus as a result of vascular endothelium damage during injection. We present a pulmonary FDG microembolus in a patient evaluated for suspicion of gallbladder cancer not in early (standard 1-hour imaging after FDG injection) but in delayed image. To our knowledge, this is the first case that describes the possibility of FDG microembolism on only delayed image in a PET/CT study.
SP0034 How to treat ANCA-associated vasculitis
Authors: L. Guillevin
Journal: Annals of the Rheumatic Diseases (2013)

Treatment of ANCA-associated vasculitides is better codified and new strategies improved diseases outcome. Induction treatment comprises steroids and cytotoxic agents. In the long term, steroids should be prescribed at the lowest effective dose. They should be maintained for 12 to 24 months and during the second year, at 5 mg/day. Cyclophosphamide is an effective induction treatment. Pulse treatment is recommended for 4 months (6 pulses). Maintenance treatment is based on azathioprine or methotrexate prescribed for 18 to 24 months. In patients presenting with severe renal insufficiency, plasma exchanges improve renal function. Biotherapies now hold a specific place in the therapeutic armamentarium for systemic vasculitides. These therapeutics include polyvalent immunoglobulins, with now quite well defined indications, but also now some more specifically targeted monoclonal antibodies, like anti-TNF-alpha or anti-CD20 for ANCA-associated vasculitides, or anti-IL5 for Churg-Strauss syndrome. However, the exact indications of these latter new agents, as well as their optimal dosage and duration, are not yet precisely defined, mainly for maintenance therapy. Biotherapies are mostly prescribed for patients with disease refractory to conventional therapy. Prospective trials have recently demonstrated that rituximab is as effective as cyclophosphamide to induce remission of granulomatosis with polyangiitis and microscopic polyangiitis. Rituximab is now under evaluation for maintenance therapy. Other biotherapies have been evaluated. If etanercept does not seem effective, to maintain remission, infliximab is effective in severe and refractory ANCA-associated vasculitis. However relapses occur as soon the drug is stopped. It seems now reasonable to expect dramatic changes in the treatment of ANCA-associated vasculitis with a larger place for biotherapies. <h3>Disclosure of Interest</h3> L. Guillevin Grant/Research support from: rituximab was provided for a prospective institurional trial on ANCA vasculitis, Consultant for: Roche Pharma (AIR scientific council)
P257 THE ROLE OF THE ADAPTIVE IMMUNE SYSTEM IN THE DEVELOPMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE IN MORBIDLY OBESE PATIENTS
Authors: P. Iruzubieta, M.T. Arias Loste, A. Puente, J. Cabezas, D. San Segundo, A. Azueta, C. Santa Cruz, A. Estebanez, A. López Useros, A. Domínguez, M. López Hoyos, J. Crespo
Journal: Journal of Hepatology (2014)
Surgeon whose "mistake" left four year old boy with colostomy bag gets three month suspension
Authors: C. Dyer
Journal: BMJ (2012)

A consultant paediatric surgeon who injected a 4 year old boy with a potentially fatal 80% solution of phenol after removing a haemorrhoid has been suspended from practice for three months for his “catastrophic” error.

Gyorgy Rakoczy told a General Medical Council fitness to practise panel that he had “nightmares” after the mistake, which meant that the boy had to have part of his bowel removed and be fitted with a colostomy bag.

Rakoczy was handed the 80% liquid phenol by a nurse, instead of 5% oily …
SP0097 Completing Patient Reported Outcomes: Does IT Improve My Care?
Authors: M. Ernst
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> As I am not only a patient myself but also a health professional working in a rheumatological outpatient department, I have the unique chance of being able to provide various points of view and insights regarding this question. First I am going to present the daily routine of the outpatient department at the General Hospital in Vienna. I will describe which patient reported outcome measures are used and how data is processed there. To gain comprehensive data regarding the question above, I interviewed various patients of our department. They were of different age, disease activity and gender. On the basis of these conversations, I was able to gain a broad and detailed spectrum of sentiments and could compare my point of view to those of people not working in health care. I am going to filter out some highlights and elaborate on the following three main questions that emerged: – What do you think why are you asked to fill in the different questionnaires? – Have you any idea what happens with the completed forms? – Do you think it has an impact on your treatment and care? At the end of my talk, I will gladly take questions or partake in an exchange of views and experiences. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6197
Expression profile of <i>CYP19</i> in human breast cancer cell lines treated with indole-3-carbinol, 3,3'-diindolylmethane, and sulforaphane.
Authors: BE Licznerska, I Matuszak, W Baer-Dubowska
Journal: Cancer Research (2009)

Abstract Abstract #1113 Breast cancer is the most frequently diagnosed cancer in Western women. Most cases (up to 75%) are estrogen-dependent. The estrogen-independent cases are more invasive, more difficult to treat, and they are connected with worse prognosis. The biologically active estrogens important in the proliferation of breast cancer are produced from inactive precursors by the action of aromatase encoded by CYP19 gene. Conventional treatment (e.i. hormonal therapy) is expensive and for advanced cancer ultimately unsuccessful. That is why early diagnosis and prevention of this disease is urgently needed. A new hope is brought by chemoprevention – the concept of early intervention by usage of different agents inhibiting the development of invasive cancer. Recent epidemiological migrant studies showed that consumption of raw or short cooked cabbage and sauerkraut is connected with significant reduction of breast cancer incidences. Indole-3-carbinol (I3C), 3,3'-diindolylmethane (DIM) – a major in vivo acid-catalyzed condensation product of I3C, and sulforaphane (SUL) are examples of numerous active chemicals in cabbage.&amp;#x2028; The aim of the present study was to investigate the effect of I3C, DIM and SUL on the profile of CYP19 expression in human breast cancer estrogen-dependent MCF-7 cell line. Cells were treated with these compounds at the concentrations relevant to those observed in human plasma. The total RNA extraction from cell cultures after 144 hours of incubation with different substances concentrations and reverse transcriptase reaction preceded the cDNA synthesis. The screening of cDNA from aromatase mRNA was performed using real-time PCR assay. The results showed that I3C in the dose of 30 μM reduced the expression of CYP19 in MCF-7 cell line. In contrast, higher dose of I3C (50 μM) induced its expression. The latter results confirmed the observations of the other authors indicating reciprocal I3C effect on carcinogenesis. SUL in the doses of 5μM and 20μM diminished the level of CYP19 mRNA. Similar trend was observed after treatment with 5 μM and 10 μM of DIM. Since the down-regulation of CYP19 gene causes the reduction in estrogens synthesis the usage of I3C, DIM, and/or SUL could be well-founded as preventive agents against breast carcinoma development. Further investigation on estrogen-independent MDA-MB-231 cell line which is under way are necessary to compare the possible application of I3C, DIM, and SUL as a chemopreventive agents depending on the hormonal character of the tumour. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1113.
Abstract 1876: Adolescent and mid-life diet: risk of pancreatic cancer in the NIH-AARP Diet and Health Study
Authors: Kristin A. Moy, Nancy Potischman, Frances E. Thompson, Amy Subar, Elizabeth H. Ruder, Anne C.M. Thiebaut, Rachael Z. Stolzenberg-Solomon
Journal: Cancer Research (2015)

Abstract Background: To date, the data concerning diet and pancreatic cancer risk has focused on diet assessed during adulthood. Given the long latency period of this malignancy, examining diet during adolescence and midlife may shed light on the diet - pancreatic cancer association. Methods: We examined the associations between diet at ages 12-13 years, 10 years before baseline (ages 40-61 years), and the joint effects of both with risk of pancreatic cancer in the NIH-AARP Diet and Health Study. Six months after baseline, 303,094 individuals (175,991 men and 127,103 women) completed two 37-item food frequency questionnaires that assessed diet at ages 12-13 years and 10 years previously. Cox proportional hazards regression was used to estimate smoking, body mass index, and diabetes adjusted multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for pancreatic cancers (n = 1,322 by the end of 2006). Results: Comparing highest to the lowest tertile (T3 vs. T1), carbohydrate intake at age 12-13 (HR (95% CI): 0.86 (0.75, 0.98), P-trend = 0.06) and 10 years before baseline (HR (95% CI): 0.87 (0.76, 1.00), P-trend = 0.05) were inversely associated with pancreatic cancer. Intake of total fat at ages 12-13 (HR (95% CI): 1.15 (1.00, 1.33), P-trend = 0.07) and 10 years before baseline (HR (95% CI): 1.18 (1.03, 1.35), P-trend = 0.02) were positively associated with risk. High intake of fat in both adolescence and midlife was positively associated with risk (HR (95% CI): 1.32 (1.08, 1.62)). Calcium intake 10 years before baseline was associated with reduced risk (T3 vs T1 HR (95% CI): 0.88 (0.77, 1.00), P-trend = 0.05) as was changing from low intake in adolescence to high intake in midlife (HR (95% CI): 0.71 (0.54, 0.93)). Solid fat (butter and margarine) intake 10 years before baseline was associated with increased risk (T3 vs T1 HR (95% CI): 1.23 (1.06, 1.42), P-trend = 0.005) as was consumption of solid fats at both time points (HR (95% CI): 1.31 (1.08, 1.60)). Conclusion: Diet during adolescence and midlife may play a role in the etiology of pancreatic cancer. Citation Format: Kristin A. Moy, Nancy Potischman, Frances E. Thompson, Amy Subar, Elizabeth H. Ruder, Anne C.M. Thiebaut, Rachael Z. Stolzenberg-Solomon. Adolescent and mid-life diet: risk of pancreatic cancer in the NIH-AARP Diet and Health Study. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1876. doi:10.1158/1538-7445.AM2015-1876
1234 REEMERGING HEPATITIS E EPIDEMIC IN SAPPORO, JAPAN, CAUSED BY A MONOPHYLETIC AND VIRULANT HEV STRAIN WITHIN GENOTYPE 4
Authors: J.-H. Kang, Y. Karino, H. Mizuo, K. Takahashi, M. Arai, H. Okamoto, S. Mishiro
Journal: Journal of Hepatology (2013)
P824 SOLUBLE CD163, A MACROPHAGE ACTIVATION MARKER, IS INDEPENDENTLY ASSOCIATED WITH STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Authors: K. Kazankov, F. Barrera, H.J. Møller, H. Vilstrup, J. George, H. Grønbæk
Journal: Journal of Hepatology (2014)